Integra LifeSciences Stock Rises On Street-Beating Q3 Earnings, Raises FY21 EPS Guidance

Loading...
Loading...
  • Integra LifeSciences Holdings Corporation IART shares got a boost as Q3 adjusted EPS of $0.86 topped the consensus forecast of $0.72.
  • Revenues increased 4.5% Y/Y (6.7% organically) to $386.9 million, beating the consensus of 384.58 million, due to higher sales from instruments and Wound Reconstruction & Care.
  •  “Strength across most of our product portfolio, driven by commercial and operational execution and a contribution from our recently launched CereLink ICP monitor, led to third-quarter results near the high end of our guidance range, despite ongoing COVID and supply challenges,” said Integra President & CEO Peter Arduini.
  • The adjusted gross margin was 68.3%, compared to 68.6% in the prior year.
  • The adjusted EBITDA reached $104.32 million, up from $103.15 million a year ago.
  • Cash flow from operations of $82.8 million increased by 18.9%.
  • Guidance: Integra raised its adjusted EPS projections for FY21 from $2.98 - $3.05 to $3.16 - $3.20 (consensus $$3.02). 
  • The Company also reaffirmed sales guidance of $1.54 billion - $1.55 billion, with expectations of coming in at the low end of the range.
  • Price Action: IART shares closed higher by 8.88% at $73.25 on Tuesday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...